Eurofarma
Eurofarma, officially known as Eurofarma Laboratórios S.A., is a prominent Brazilian pharmaceutical company headquartered in São Paulo, Brazil. Established in 1972, Eurofarma has grown to become a key player in the Latin American pharmaceutical industry, with a strong presence across various operational regions, including Central and South America. Specialising in the development, manufacturing, and marketing of prescription medicines, generics, and over-the-counter products, Eurofarma is recognised for its commitment to quality and innovation. The company’s diverse portfolio includes therapeutic areas such as oncology, cardiology, and central nervous system disorders, setting it apart with its focus on patient-centric solutions. With a robust market position, Eurofarma has achieved significant milestones, including numerous certifications and awards for excellence in pharmaceutical practices, reinforcing its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Eurofarma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eurofarma's score of 36 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Eurofarma's reported carbon emissions
In 2023, Eurofarma reported total carbon emissions of approximately 42,183,000 kg CO2e. This figure includes 16,990,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 7,963,000 kg CO2e from Scope 2 emissions, related to purchased electricity. Notably, Scope 3 emissions accounted for about 17,230,000 kg CO2e, primarily from upstream activities such as purchased goods and services, as well as employee commuting. In comparison, the company's emissions in 2022 were approximately 36,071,000 kg CO2e, indicating a rise in emissions year-on-year. The breakdown for 2022 included 22,210,000 kg CO2e from Scope 1, 9,048,000 kg CO2e from Scope 2, and 4,813,000 kg CO2e from Scope 3. Eurofarma has not publicly committed to specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or similar frameworks. However, the company continues to monitor and report its emissions across all three scopes, demonstrating a commitment to transparency in its climate impact. Overall, Eurofarma's emissions data reflects the challenges faced by the pharmaceutical industry in managing carbon footprints while striving for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 12,594,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 4,611,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 6,146,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eurofarma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
